Literature DB >> 26938661

Sudden acquired retinal degeneration in dogs: breed distribution of 495 canines.

Amanda R Heller1, Alexandra van der Woerdt1, James E Gaarder2, John S Sapienza3, Elena Hernandez-Merino3, Kenneth Abrams4, Melanie L Church5, Noelle La Croix6.   

Abstract

PURPOSE: The purpose of this study was to describe breed, age, gender, and weight distribution of dogs affected with sudden acquired retinal degeneration (SARD) and to investigate whether SARD is more common in small breed dogs.
METHODS: Medical records of dogs diagnosed with SARD confirmed by an electroretinogram were reviewed. Breed, age, gender, and weight were recorded when available. The same data were obtained for dogs with SARD described in the veterinary literature.
RESULTS: Three hundred and two dogs were included from the ophthalmology practices and 193 dogs from the veterinary literature. Sixty breeds were present in the study. Mixed-breed dogs were the most common at 108 dogs (21.8%), followed by the Dachshund (68, 13.7%), Chinese Pug (44, 8.9%), Miniature Schnauzer (39, 7.9%), Maltese (23, 4.6%), Cocker Spaniel (22, 4.4%), Bichon Frise (18, 3.6%), Beagle (16, 3.2%), Brittany (15, 3.0%), and Pomeranian (10, 2.0%). Fifty other breeds were represented by 1-9 dogs each. The median age was 9 years (range = 10 months-16 years). The weight was known for 197 dogs. About 60.9% of dogs were less than 25 pounds, 31.5% were between 25 and 50 pounds, and 7.6% were greater than 50 pounds. Gender was recorded in 393 dogs: 217 female dogs and 176 male dogs.
CONCLUSIONS: As previously reported, SARD is most common in middle-aged to older dogs. Smaller dogs of less than 25 pounds appear overrepresented, while large/giant breed dogs of greater than 50 pounds are infrequently diagnosed. In this study, there was no statistical significance between female and male dogs.
© 2016 American College of Veterinary Ophthalmologists.

Entities:  

Keywords:  blindness; dogs; sudden acquired retinal degeneration

Mesh:

Year:  2016        PMID: 26938661     DOI: 10.1111/vop.12370

Source DB:  PubMed          Journal:  Vet Ophthalmol        ISSN: 1463-5216            Impact factor:   1.644


  6 in total

1.  Sudden acquired retinal degeneration syndrome in western Canada: 93 cases.

Authors:  Marina L Leis; Danica Lucyshyn; Bianca S Bauer; Bruce H Grahn; Lynne S Sandmeyer
Journal:  Can Vet J       Date:  2017-11       Impact factor: 1.008

2.  Canine sudden acquired retinal degeneration syndrome: Owner perceptions on the time to vision loss, treatment outcomes, and prognosis for life.

Authors:  Demitrius R Washington; Zhanhai Li; Lani C Fox; Freya M Mowat
Journal:  Vet Ophthalmol       Date:  2020-12-29       Impact factor: 1.644

3.  Optical coherence tomography and molecular analysis of sudden acquired retinal degeneration syndrome (SARDS) eyes suggests the immune-mediated nature of retinal damage.

Authors:  Sinisa D Grozdanic; Tatjana Lazic; Helga Kecova; Kabhilan Mohan; Markus H Kuehn
Journal:  Vet Ophthalmol       Date:  2018-08-15       Impact factor: 1.644

4.  Evaluation of the major histocompatibility complex (MHC) class II as a candidate for sudden acquired retinal degeneration syndrome (SARDS) in Dachshunds.

Authors:  Stephanie J Stromberg; Sara M Thomasy; Ariana D Marangakis; Soohyun Kim; Ann E Cooper; Emily A Brown; David J Maggs; Danika L Bannasch
Journal:  Vet Ophthalmol       Date:  2019-02-21       Impact factor: 1.644

5.  Circulating neurohormone imbalances in canine sudden acquired retinal degeneration syndrome and canine pituitary-dependent hypercortisolism.

Authors:  Annie Oh; Melanie L Foster; Katharine F Lunn; Freya M Mowat
Journal:  J Vet Intern Med       Date:  2019-10-29       Impact factor: 3.333

6.  A potential early clinical phenotype of necrotizing meningoencephalitis in genetically at-risk pug dogs.

Authors:  Rebecca Windsor; Samuel Stewart; Jessica Schmidt; Mario Mosqueda; Ignazio Piras; Stefan M Keller; Briana Steinmetz; Dori L Borjesson; Matthew Huentelman; Chand Khanna
Journal:  J Vet Intern Med       Date:  2022-05-27       Impact factor: 3.175

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.